An increase suggests successful leverage of external partnerships to drive sales, while a decrease may indicate expiring agreements or shifting commercial strategies.
Revenue generated through collaborative arrangements, co-promotion agreements, or profit-sharing partnerships with other...
Commonly reported by large pharma firms as 'collaboration revenue' or 'co-promotion income' in peer financial statements.
pfe_alliance_revenues| Segment | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 |
|---|---|---|---|---|---|---|---|---|
| Epkinly | $14.00M | $14.00M | $22.00M | $29.00M | $31.00M | $36.00M | $36.00M | $49.00M |
| Total | — | — | — | — | — | — | — | — |
Epkinly was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| International | $230.00M | $228.00M | $238.00M | $210.00M | $209.00M | $211.00M | $199.00M | $224.00M |
| Total | — | — | — | — | — | — | — | — |